KYV-101 anti-CD19 CAR-T cell therapy
KYSA-3
Phase 2 mab active
Quick answer
KYV-101 anti-CD19 CAR-T cell therapy for Lupus Nephritis is a Phase 2 program (mab) at Kyverna Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Kyverna Therapeutics
- Indication
- Lupus Nephritis
- Phase
- Phase 2
- Modality
- mab
- Status
- active